The Lynch Companies

The Lynch Companies is a regenerative medicine organization focused on the development and commercialization of advanced tissue engineering products. Led by Dr. Samuel Lynch, the company operates primarily through its subsidiaries, Lynch Biologics and Lynch Regenerative Medicine, to provide growth-factor based therapies. Their core technology utilizes recombinant human platelet-derived growth factor (rhPDGF-BB) to stimulate cellular proliferation and angiogenesis for bone and soft tissue repair. The company's flagship commercial product, GEM 21S, is a widely recognized grafting system used in periodontal surgery to treat bone defects. Beyond dentistry, the company is expanding its pipeline into wound care and orthopedic applications.